The company is down since yesterday's close of 95.43. The institutional investor held 105,852 shares of the containers and packaging company at the end of 2017Q2, valued at $4.47 million, up from 52,926 at the end of the previous reported quarter.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. Needham maintained the stock with "Buy" rating in Tuesday, November 7 report. About 433,090 shares traded. Pekin Singer Strauss Asset Il reported 0.6% of its portfolio in AbbVie Inc (NYSE:ABBV).
Legal & General Group Plc boosted its stake in shares of AbbVie by 1.7% in the second quarter. In the last ninety days, insiders have sold 58,932 shares of company stock worth $5,379,432. The stock declined 1.35% or $1.28 reaching $93.85 per share. Another trade for 20,960 shares valued at $869,329 was sold by Pauley Lisa Ann.
Palladium Partners LLC cut its position in shares of AbbVie Inc. It has underperformed by 6.07% the S&P500. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the stock.
TRADEMARK VIOLATION WARNING: "AbbVie Inc". The firm has "Buy" rating by Jefferies given on Friday, August 5. The stock has "Hold" rating by BMO Capital Markets on Thursday, April 13. SunTrust Banks, Inc. reaffirmed a "buy" rating and issued a $95.00 price target on shares of AbbVie in a report on Wednesday, September 13th. BidaskClub lowered shares of AbbVie from a "buy" rating to a "hold" rating in a report on Friday, August 4th. The stock of Oracle Corporation (NYSE:ORCL) earned "Buy" rating by Nomura on Thursday, September 17. 156,838 were accumulated by Kcm Ltd. Rand Wealth Lc holds 45,484 shares. Needham maintained Dermira Inc (NASDAQ:DERM) on Friday, September 15 with "Buy" rating. Jefferies Group LLC upped their price target on shares of AbbVie from $107.00 to $115.00 and gave the stock a "buy" rating in a research note on Monday, October 16th. The stock has "Hold" rating by BMO Capital Markets on Wednesday, June 7.
AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. "Buys DowDuPont Inc, Red Hat Inc, AbbVie ..." on November 02, 2017. (NYSE:ABBV) by 7.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission.
Since May 18, 2017, it had 0 insider purchases, and 3 sales for $13.46 million activity. Koshinski Asset Mgmt has 0% invested in AbbVie Inc (NYSE:ABBV) for 11,770 shares. 1,312 shares were sold by Griffith Christopher M. The shares were sold at an average price of $94.69, for a total transaction of $2,427,188.77.
Investors sentiment increased to 1 in Q2 2017. Its down 0.50, from 1.89 in 2017Q1.
As of now, the increased share price of AbbVie Inc. makes it a lucrative buy for investors. BlackRock Institutional Trust Company N.A. raised its position in AbbVie by 0.9% in the second quarter. Overbrook Mgmt accumulated 44,667 shares. Mason Street Limited Liability reported 48,592 shares. Mufg Americas Holdg Corporation holds 0.13% or 55,490 shares in its portfolio. Sky Investment Ltd Liability Corp invested in 12,505 shares or 0.38% of the stock. 20,993 were reported by Cypress Asset Mngmt Tx. Culbertson A N & has invested 1.98% in AbbVie Inc (NYSE:ABBV). Bancorp Of Nova Scotia has 8,324 shares for 0.07% of their portfolio. Legacy Capital holds 2.31% or 58,919 shares. Cowen & Co downgraded AbbVie Inc (NYSE:ABBV) on Monday, June 6 to "Market Perform" rating. Campbell Newman Asset Incorporated reported 0.33% stake. Moreover, Americafirst Capital Limited Liability has 1.54% invested in AbbVie Inc (NYSE:ABBV). Conning reported 53,134 shares. The Associated Banc-Corp holds 65,907 shares with $4.78M value, down from 83,425 last quarter. L S Advisors reported 130,815 shares. Abbvie Inc had 66 analyst reports since July 21, 2015 according to SRatingsIntel. ABBV's profit will be $2.28B for 16.41 P/E if the $1.43 EPS becomes a reality. AbbVie's quarterly revenue was up 8.8% on a year-over-year basis. Its stake was valued at $687,591,000 an increase of $123,944,000 as of quarter end. Palisade Asset Management LLC now owns 68,311 shares of the company's stock worth $4,953,000 after buying an additional 10,381 shares in the last quarter. More interesting news about AbbVie Inc (NYSE:ABBV) were released by: Seekingalpha.com and their article: "AbbVie inks $225M neurodegenerative drug development deal with Alector" published on October 24, 2017 as well as Nasdaq.com's news article titled: "Can AbbVie (ABBV) Spring a Surprise this Earnings Season?" with publication date: October 24, 2017. Its up 0.01, from 0.99 in 2017Q1. HOOVER R DAVID had sold 22,000 shares worth $874,503 on Thursday, May 18. 62 funds opened positions while 297 raised stakes. Psagot Inv House Limited holds 15,600 shares or 0.05% of its portfolio. This defines the most likely future of the stock price of AbbVie Inc. Rhumbline Advisers invested 0% in Dermira Inc (NASDAQ:DERM). Wright Invsts Serv Inc owns 51,555 shares. Edgar Lomax Va stated it has 145,111 shares. Sei Invs owns 104,691 shares or 0% of their U.S. portfolio. Glenview Natl Bank Tru Dept holds 33,640 shares. Metropolitan Life Insur Ny reported 39,027 shares stake. "(ABBV) Given New $115.00 Price Target at Piper Jaffray Companies" was reported by TrueBlueTribune and is the property of of TrueBlueTribune. 1,530 were reported by Point72 Asia (Hong Kong) Ltd.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.